We are reporting from the 2020 ESMO Virtual Congress!
We are recapping some of the top news that are being presented during the conference—and in just a bit we’ll be speaking with Dr Robert Coleman to get his take on the biggest abstracts in gynecologic cancers, and also with Dr Shilpa Gupta on the latest in genitourinary cancers.
Welcome to OncLive News Network! I’m Gina Mauro.
In renal cell carcinoma, results of the phase 3 CheckMate-9ER trial showed that the combination of nivolumab and cabozantinib was found to double progression-free survival and objective response rates, and also significantly improve overall survival, compared with sunitinib, in patients with advanced disease who have not received prior treatment.
In basal cell carcinoma, the PD-1 antibody cemiplimab established encouraging clinical activity in patients with locally advanced disease who progress on or are intolerant to hedgehog inhibitors, regardless of PD-L1 expression, according to primary cohort results of a phase 2 trial presented during the meeting.
In an interim analysis of a subset of patients with intrahepatic cholangiocarcinoma harboring FGFR2 fusions/rearrangements, the oral small molecule inhibitor futibatinib was shown to be efficacious and tolerable. Investigators recorded a 37.3% objective response rate in the analysis of 67 patients with at least 6 months of follow-up. One patient had complete response and 24 patients had partial response.
Findings from the phase 3 IPATunity trial showed that the combination of ipatasertib plus paclitaxel did not improve efficacy in patients with PIK3CA/AKT1/PTEN-altered hormone receptor–positive advanced breast cancer. However, follow-up for overall survival is ongoing.
A subgroup analysis from the phase 3 JAVELIN Bladder 100 trial demonstrated that frontline maintenance therapy with avelumab plus best supportive care provided an overall survival benefit compared with best supportive care alone across prespecified subgroups of patients whose disease had not progressed with frontline induction chemotherapy. Avelumab was approved by the FDA earlier in 2020 for this indication.
Two phase 2 trials in cervical cancer showcased activity with the PD-1 inhibitor balstilimab in patients with recurrent/metastatic disease. As a single agent, he response rate was 14% of all patients with the disease 19% in PD-L1–positive patients. For patients who received balstilimab plus the CTLA-4 inhibitor zalifrelimab, the ORRs were 22% and 27% in PD-L1–positive patients with recurrent/metastatic cervical cancer, respectively.
A first-in-human trial showed that the novel FAP-targeted 4-1BB agonist RO7122290 demonstrated an acceptable safety profile as a single agent and in combination with atezolizumab. Moreover, there were favorable pharmacokinetic and pharmacodynamic effects, and the preliminary antitumor activity supports further investigation in clinical trials.
For more coverage of the 2020 ESMO Virtual Congress, please be sure to visit onclive.com.
That’s all for today. Tomorrow on OncLive News Network: On Location, we’ll speak with Dr Scott Tagawa to get perspectives on other studies being presentted in genitourinary cancers, and Dr Stephen Liu to get the latest ESMO abstracts in lung cancer.
Thank you for watching OncLive News Network! I’m Gina Mauro.
Which of the following stories from the 2020 ESMO Virtual Congress did you find most exciting?
Join oncologists nationwide who have learned from the top leaders in the lung cancer field as they share their insights on coronavirus disease 2019 (COVID-19) and how the pandemic is poised to have a significant impact on lung cancer treatment and the health care system. Led by Nathan A. Pennell, MD, PhD; Stephen Liu, MD; H. Jack West, MD; Charu Aggarwal, MD, MPH, this webinar will cover all of the key information on treating your patients with lung cancer, who could be at risk for developing COVID-19.
Nathan A. Pennell, MD, PhD, Associate Professor; Director, Lung Cancer Medical Oncology Program,Cleveland Clinic, Cleveland, OH
Stephen Liu, MD, Associate Professor of Medicine; Director, Thoracic Oncology, Georgetown University, Washington, DC
Charu Aggarwal, MD, MPH, Leslye M. Heisler Assistant Professor of Medicine, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA
H. Jack West, MD, Associate Clinical Professor in Medical Oncology; Executive Director, Employer Services, City of Hope Comprehensive
Cancer Center, Irwindale, CA
Anna F. Farago, MD, PhD, Guest Speaker; Medical Oncologist, The Center for Thoracic Cancers at Massachusetts General Hospital; Assistant Professor of Medicine, Harvard Medical School Boston, Massachusetts
This OncLive® webinar will focus on the impact of COVID-19 in patients with breast cancer and the innovative ways in which treatment has evolved during this time. We will feature a panel of experts from the nation’s leading cancer centers, led by Eric P. Winer, MD, to discuss important topics and key information for treating patients with breast cancer.
Eric P. Winer, MD
Professor, Medicine, Harvard Medical School
Director, Breast Oncology Center, Dana-Farber Cancer Institute
Physician Active Staff, Medicine, Brigham And Women's Hospital
Thompson Chair, Breast Cancer Research, Dana-Farber Cancer Institute
Lisa A. Carey, MD , FASCO
Richardson and Marilyn Jacobs Preyer Distinguished Professor for Breast Cancer Research
Deputy Director of Clinical Sciences
Lineberger Comprehensive Cancer Center
George W. Sledge Jr, MD
Professor, Medicine and Oncology
Chief of the Division of Oncology, Stanford University Medical Center
Monica Morrow, MD, FACS
Chief, Breast Service, Department of Surgery
Anne Burnett Windfohr Chair of Clinical Oncology
Memorial Sloan Kettering Cancer Center
Professor of Surgery, Weill Cornell Medical College
Sponsored by : Novartis / In association with Dana Farber